Cantor Fitzgerald Lifts Earnings Estimates for Prothena

Key Points

• Cantor Fitzgerald has significantly upgraded its earnings forecast for Prothena Corporation's FY2026 from **($3.66)** to **($0.25)** per share, while maintaining a **"Neutral"** rating on the stock.
• Prothena's current consensus estimate for full-year earnings stands at **($4.04)** per share, indicating a challenging financial outlook based on recent earnings performance.
• The company's stock is currently priced at **$7.64**, with a market capitalization of approximately **$410.99 million**, and has seen a notable fluctuation between a one-year low of **$4.32** and a high of **$23.66**.

Prothena Corporation plc (NASDAQ:PRTA - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2026 EPS estimates for shares of Prothena in a research note issued to investors on Tuesday, August 5th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the biotechnology company will earn ($0.25) per share for the year, up from their prior forecast of ($3.66). Cantor Fitzgerald currently has a "Neutral" rating on the stock. The consensus estimate for Prothena's current full-year earnings is ($4.04) per share.

Prothena (NASDAQ:PRTA - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.75). The firm had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million. Prothena had a negative net margin of 2,929.30% and a negative return on equity of 62.17%.

A number of other equities analysts also recently issued reports on the stock. Chardan Capital reaffirmed a "buy" rating and set a $18.00 price objective on shares of Prothena in a report on Tuesday, August 5th. Oppenheimer lowered Prothena from an "outperform" rating to a "market perform" rating in a report on Tuesday, May 27th. Piper Sandler cut their target price on Prothena from $110.00 to $81.00 and set an "overweight" rating for the company in a research note on Tuesday, May 27th. JMP Securities reduced their target price on Prothena from $78.00 to $29.00 and set a "market outperform" rating for the company in a report on Tuesday, May 27th. Finally, Jefferies Financial Group cut Prothena from a "buy" rating to a "hold" rating and set a $6.00 target price on the stock. in a report on Tuesday, May 27th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $30.25.

Prothena Trading Down 0.5%

Prothena stock traded down $0.04 during trading hours on Thursday, reaching $7.65. 640,660 shares of the stock were exchanged, compared to its average volume of 1,061,299. The stock has a 50 day moving average of $6.20 and a two-hundred day moving average of $9.60. Prothena has a twelve month low of $4.32 and a twelve month high of $22.83. The company has a market cap of $411.80 million, a P/E ratio of -1.36 and a beta of -0.03.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Virtus ETF Advisers LLC increased its stake in shares of Prothena by 19.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock worth $71,000 after acquiring an additional 833 shares during the last quarter. GAMMA Investing LLC raised its holdings in Prothena by 4,626.0% in the first quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company's stock valued at $74,000 after acquiring an additional 5,875 shares in the last quarter. Prospera Financial Services Inc purchased a new stake in shares of Prothena during the 2nd quarter worth $61,000. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Prothena in the 1st quarter worth about $126,000. Finally, Cary Street Partners Financial LLC purchased a new position in Prothena in the 4th quarter valued at about $173,000. 97.08% of the stock is owned by hedge funds and other institutional investors.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.